Troxipide

• Description :

  Troxipide is an orally active defensive factor-enhancing therapeutic agent for gastritis and gastric ulcer (GU) . Troxipide is a non-antisecretory gastro protective agent with antiulcer, anti-inflammatory and mucus-secreting properties[1][2].

• CAS Number :

  [30751-05-4]

• UNSPSC :

  12352005

• Hazard Statement :

  H315, H319

• Target :

  Others

• Type :

  Reference compound

• Related Pathways :

  Others

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/Troxipide.html

• Purity :

  99.62

• Solubility :

  DMSO : 9.09 mg/mL (ultrasonic) |H2O : 1 mg/mL (ultrasonic; warming; heat to 80°C)

• Smiles :

  O=C(NC1CNCCC1)C2=CC(OC)=C(OC)C(OC)=C2

• Molecular Formula :

  C15H22N2O4

• Molecular Weight :

  294.35

• Precautions :

  H315, H319

• References & Citations :

  [1]Hongbin Guo, et al. Metabolites profiling and pharmacokinetics of troxipide and its pharmacodynamics in rats with gastric ulcer. Sci Rep. 2020 Aug 12;10 (1) :13619.|[2]K Kusugami, et al. Troxipide, a novel antiulcer compound, has inhibitory effects on human neutrophil migration and activation induced by various stimulants. Dig Liver Dis. 2000 May;32 (4) :305-11.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched